Citadel Advisors’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Citadel Advisors’s Portfolio AVNR Stock Details AVNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,691,547	Closed	-$23.8M	–	9006
2014 Q3	$20.2M	Buy	1,691,547 +491,925	+41%	+$3.36M	0.02%	898
2014 Q2	$6.77M	Buy	1,199,622 +1,187,128	+9,502%	+$5.47M	0.01%	1580
2014 Q1	$46K	Sell	12,494 -102,582	-89%	-$391K	﹤0.01%	6842
2013 Q4	$386K	Sell	115,076 -26,739	-19%	-$110K	﹤0.01%	4311
2013 Q3	$602K	Buy	141,815 +55,835	+65%	+$265K	﹤0.01%	3601
2013 Q2	$396K	Buy	+85,980	New	+$296K	﹤0.01%	4068

Citadel Advisors's AVNR Position: Q4 2014 in Review

Citadel Advisors sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q4 2014, closing a stake of 1,691,547 shares — an estimated $23.8M sold.

Citadel Advisors first reported a position in AVNR in Q2 2013 and held it in 6 quarters. The position peaked at $20.2M in Q3 2014. 166 funds tracked by Wall St. Rank hold AVNR as of Q4 2014.

Citadel Advisors reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q4 2014 after selling out during the quarter.
Citadel Advisors sold 1,691,547 AVANIR PHARMACEUTICALS, INC CL A shares in Q4 2014, an estimated $23.8M.
Citadel Advisors first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 6 quarters.
Citadel Advisors's AVANIR PHARMACEUTICALS, INC CL A position peaked at $20.2M in Q3 2014.
166 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q4 2014.

Based on Citadel Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.